Skip to main content

Table 2 Evolution of DMARD treatment and disease during the first year for ESPOIR patients with early rheumatoid arthritis (RA).

From: Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort

First DMARD    Treatment at 1 year    
Type N Delay between RA onset and DMARD start (weeks)a   N DAS28(ESR)-4v at baseline DAS28(ESR)-4v at 1 year
Methotrexateb 335 26.7 ± 11.6 (24.3) Methotrexate 302 5.3 ± 1.3 (5.2) 3.2 ± 2.7 (3.0)
   35 ± 15.3 (39.4) Other synthetic DMARD(s)c 19 5.3 ± 1.4 (5.3) 4.1 ± 1.5 (4.1)
   30.5 ± 0.7 (21.6) Biologic agentd 11 5.7 ± 0.4 (5.5) 3.9 ± 0.9 (4.2)
Leflunomide 35 48.9 ± 11.6 (46.9) Methotrexate 9 5.8 ± 1.3 (5.6) 4.0 ± 2.7 (2.9)
   22.5 ± 15.3 (20.7) Other synthetic DMARD(s) 24 5.4 ± 1.4 (5.5) 3.3 ± 1.5 (3.0)
   37.8 ± 0.7 (37.8) Biologic agentd 2 5.9 ± 0.4 (5.9) 4.2 ± 0.9 (4.2)
  1. Data are mean ± SD (median). aDelay between RA onset and DMARD start (weeks) (P = 0.479): Methotrexate: 27.2 ± 15.1 (24.7); Leflunomide: 30.1 ± 18.1 (24.6); bat one year: one patient did not receive any DMARDs and data for two patients were not available; cleflunomide or salazopyrine; dadalinumab, etanercept, infliximab or anakinra. DAS28(ESR)-4v, Disease Activity Score in 28 joints-4 variables, using erythrocyte sedimentation rate; DMARD, disease-modifying anti-rheumatic drugs; N, number.